Paul KENNY (Friedman Brain Institute (FBI), Director of the Drug Discovery Institute and Director of the NIDA T32 Training Program in Substance Use Disorders at the Icahn School of Medicine at Mont Sinai).

The Kenny Laboratory is focused on understanding the neurobiological mechanisms of drug addiction, obesity and schizophrenia, with an emphasis on the role of nicotinic acetylcholine receptors (nAChRs) in the processes. They employ a multidisciplinary approach that includes complex behavioural paradigms, physiological analyses and molecular biological techniques. Current projects include the utilization of vector-based delivery systems to modify gene expression in the brains of rodents to identify novel signaling cascades that may play a role in addiction-like behaviours.